Tag: Cancer Drugs

Myovant Sciences Reported Positive Phase III Study of Relugolix

cancer drugs
Shares in Myovant Sciences jumped as much as 178% on Tuesday after the company reported that a Phase III study of relugolix in men with advanced prostate cancer met its primary efficacy endpoint and a...

Clinical Trials of a New Russian Cancer Drug to Begin in 2020

cancer treatment
Clinical trials of a combined drug developed by Novosibirsk scientists for the fight against cancer are planned to begin in 2020, said Vladimir Richter, deputy director of the Institute of Chemical Bi...

Chinese Authorities Accept Chi-Med Application for Surufatinib

china street
Hutchison China MediTech Limited announces that its New Drug Application for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine tumors has been accepted for review b...

Clinical Study of Avelumab Didn’t Met Primary Endpoints

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelu...

Seattle Genetics and BeiGene Entered into License Agreement

beigene
Seattle Genetics, Inc. and BeiGene, Ltd. announced that the companies have entered into a license agreement for an advanced preclinical product candidate for treating cancer. The agent utilizes a prop...

Sechenov University Launched CT to Create “Ideal” Protocol for Managing Early-Stage Prostate Cancer

Early stages of prostate cancer are best left for watchful waiting. As cancer can take years and even decades to develop, “cutting the patient open” right away might not be the preferable solution. It...

EC Approved BAVENCIO® for Advanced Renal Cell Carcinoma Treatment

merck kgaa
Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. announced that the European Commission (EC) has approved BAVENCIO® (av...

Seattle Genetics Ready to File Tucatinib

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease. The HER2CLIMB trial compar...

European Commission Approved Astellas Therapy XOSPATA™

drug-development
Astellas Pharma Inc. announced that the European Commission (EC) has approved the oral once-daily therapy XOSPATA™ (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or ...

BMS Gets EC Approval for Opdivo

bms
Bristol-Myers Squibb Company announced that the European Commission (EC) has approved Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused ...

GSK Secured FDA Approval for Zejula

gsk
GlaxoSmithKline (GSK) has secured expanded approval from the US Food and Drug Administration (FDA) for its Zejula (niraparib) for the late-line treatment for women with recurrent ovarian cancer. ...

Mabscale Began Clinical Trials of Trastuzumab Bio-Analog

clinical trials
The joint company of the Russian pharmaceutical enterprises Ozon and PharmEco, Mabscale, began clinical trials of a phase I comparison of a bio-analog of its own trastuzumab with the original Hercepti...

Roche Announced Positive Phase III Study of Tecentriq® in Combination with Avastin®

roche
Roche announced that the Phase III IMbrave150 study, evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinom...

Eli Lilly’s Cancer Drug Failed in Clinical Trials

eli lilly
Eli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in phase 3 pancreatic cancer trial. The big US pharma said top-line results from the phase 3 SEQUO...

Rucaparib Approved by NICE for Cancer Drugs Fund

cancer drugs
Rucaparib can now be offered to women with relapsed ovarian, fallopian tube or peritoneal cancer, that has responded to platinum-based chemotherapy. Taken as a tablet, twice daily, it slows the progre...

BMS Registered New Indication for Opdivo in Russia

Bristol-Myers Squibb Company announced that it has registered in Russia a new indication for the immuno-oncological drug Opdivo® (nivolumab), namely, as a monotherapy for common or recurrent cancer of...